Subarachnoid hemorrhage
Conditions
Interventions
Placebo group :Administer a placebo (starch).
drug intervention group:Administration of Clemastine Fumarate.
Sponsors
The Wuxi No.2 People Hospital (Jiangnan University Affiliated Central Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Demographic characteristics: 18 = 60 ml/min; II. Normal coagulation: platelet count >= 100×10?/L, INR <= 1.2.
Exclusion criteria
Exclusion criteria: Disease-related exclusions: 1. Combined with other intracranial lesions: uncontrolled intracranial tumors (except benign tumors requiring treatment), arteriovenous malformations, moyamoya disease, etc.; 2. History of recent bleeding or surgery: intracranial hemorrhage (such as parenchymal hemorrhage, subdural hematoma) or major surgery related to non-target aneurysms within 30 days prior to surgery; 3. Severe vascular stenosis: symptomatic intracranial artery stenosis =50%, or internal carotid artery stenosis =70%. Drug-related exclusions: 1. History of allergies: known allergy to clomasten fumarate or its excipients; 2. Concomitant medications: strong CYP3A4 inhibitors (e.g., ketoconazole) and monoamine oxidase inhibitors (MAOIs), or there is a risk of drug interactions. Systemic disease exclusion: 1. Severe organ dysfunction: hepatic insufficiency (ALT>3 times the upper limit of normal), renal insufficiency (GFR 180 mmHg), severe arrhythmias (such as persistent atrial fibrillation); 3. Neurological diseases: comorbid with epilepsy, Parkinson's disease, myasthenia gravis and other diseases that may interfere with cognitive assessment. Other exclusions: 1. Pregnant or lactating females, or those who plan to become pregnant (negative urine pregnancy test before enrollment); 2. Patients with malignant tumors (requiring active treatment) or expected survival of < 1 year; 3. Psychiatric illness or cognitive impairment (e.g., dementia, schizophrenia) that makes it impossible to cooperate with the study; 4. Participation in other clinical trials has not been completed, or participation in similar intervention studies in the past 3 months; 5. Other factors (e.g., alcoholism, drug abuse) that affect the safety of the study or the reliability of the results as judged by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GOS-E;Disability Rating Scale(DRS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Rankin(mRS); | — |
Countries
China
Contacts
Public ContactZhao Xudong
the Wuxi No.2 People Hospital (Jiangnan University Affiliated Central Hospital)
Outcome results
None listed